 |
 |

Clinical Severity of Psoriasis in Last 20 Years of PUVA Study
Tamar Nijsten, MD, PhD;
Caspar W. N. Looman, PhD;
Robert S. Stern, MD
Arch Dermatol. 2007;143(9):1113-1121.
Objective To assess the severity of psoriasis over time.
Design We analyzed the results of structured dermatologic examinations administered over a 20-year period beginning 10 years after study enrollment.
Setting The PUVA [psoralen–UV-A] Follow-up Study, which is a prospective cohort study.
Patients The analyses were restricted to 815 patients (83.2% of those eligible) who underwent at least 2 of 4 possible examinations between 1985 and 2005.
Main Outcome Measure A 4-point physician global assessment (PGA).
Results The distribution of the PGA levels in the study group did not change significantly over time, except that in 2005 more patients had no psoriasis compared with patients who underwent examinations in the previous study years (9.6% vs < 5.1%, P < .03). The PGA level changed more than 1 level between examinations in only 14% of patients. Multistate Markov models estimated that patients had a likelihood of about 80% to remain at the same PGA level 1 year later. After 10 years, this likelihood varied between 19% and 53%, depending on the PGA level. Except for patients who were clear of disease at baseline, on average patients had about 1 year without psoriasis over 20 years. On average, individuals with moderate to severe disease remained at these levels for 11 or more years.
Conclusion Three decades after a large and diverse group of patients sought a cure for their psoriasis, consistent control of their psoriasis often had not been achieved.
Author Affiliations: Departments of Dermatology (Dr Nijsten) and Public Health (Dr Looman), Erasmus Medical Center, Rotterdam, the Netherlands; and Department of Dermatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts (Dr Stern).
CiteULike Connotea Del.icio.us Digg Reddit Technorati
What's this?
RELATED ARTICLE
Long-term Treatment for Severe Psoriasis: We're Halfway There, With a Long Way to Go
Joel M. Gelfand
Arch Dermatol. 2007;143(9):1191-1193.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Long-term Treatment for Severe Psoriasis: We're Halfway There, With a Long Way to Go
Gelfand
Arch Dermatol 2007;143:1191-1193.
FULL TEXT
|